{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["69(12)"],"submitter":["Sperna Weiland CJ"],"pubmed_abstract":["<h4>Background</h4>Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication of ERCP, with limited studies comparing combined prophylactic measures and their efficacy relative to individual patient risk profiles. This study aims to perform an individual patient data meta-analysis (IPDMA) to evaluate the contribution of patient and ERCP-related risk factors to PEP development and to identify the best prophylaxis strategies according to the patient's risk profile.<h4>Methods</h4>We systematically searched MEDLINE, Embase, and Cochrane databases until November 2022 for randomized controlled PEP prophylaxis trials. We invited authors to share individual patient data, including PEP risk profile and prophylaxes used. PEP incidence rates for dif"],"journal":["Digestive diseases and sciences"],"pagination":["4476-4488"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11602798"],"repository":["biostudies-literature"],"pubmed_title":["Preventive Measures and Risk Factors for Post-ERCP Pancreatitis: A Systematic Review and Individual Patient Data Meta-Analysis."],"pmcid":["PMC11602798"],"pubmed_authors":["Fogel ES","Mok SRS","Buxbaum J","Gardner TB","de Jong M","Levenick JM","Singh A","Luo H","Elmunzer BJ","van Geenen EJM","Lua GW","Akshintala VS","Siersema PD","Drenth JPH","Phillip V","Choi JH","Sperna Weiland CJ","Lai JH","Singh V"],"additional_accession":[]},"is_claimable":false,"name":"Preventive Measures and Risk Factors for Post-ERCP Pancreatitis: A Systematic Review and Individual Patient Data Meta-Analysis.","description":"<h4>Background</h4>Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication of ERCP, with limited studies comparing combined prophylactic measures and their efficacy relative to individual patient risk profiles. This study aims to perform an individual patient data meta-analysis (IPDMA) to evaluate the contribution of patient and ERCP-related risk factors to PEP development and to identify the best prophylaxis strategies according to the patient's risk profile.<h4>Methods</h4>We systematically searched MEDLINE, Embase, and Cochrane databases until November 2022 for randomized controlled PEP prophylaxis trials. We invited authors to share individual patient data, including PEP risk profile and prophylaxes used. PEP incidence rates for dif","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T02:54:29.453Z","creation":"2025-04-04T02:54:29.453Z"},"accession":"S-EPMC11602798","cross_references":{"pubmed":["39500841"],"doi":["10.1007/s10620-024-08693-2"]}}